Dr. Benito Munoz Ph.D. serves as Chief Scientific Officer of the Company. Dr. Munoz has been serving as our Chief Scientific Officer since March 2017, having served as our Executive Vice President, Drug Discovery from September 2016 to March 2017. Previously, Dr. Munoz served as our Senior Vice President, Drug Discovery from December 2015 to August 2016 and as our Vice President, Medicinal Chemistry from November 2013 to December 2015. From February 2009 to November 2013, he served as the Director of Medicinal Chemistry, Molecular Libraries Probe Productions Center Network, at the Broad Institute, a biomedical research institute affiliated with Harvard University and the Massachusetts Institute of Technology. In his role at the Broad Institute, Dr. Munoz was responsible for designing and implementing a phenotypic screening platform to identify active molecules within Broad’s collection of small molecules which generated potent hits with a therapeutic potential in neglected diseases. From October 1999 to October 2008, he served in a number of positions of increasing responsibility at Merck & Co. (NYSE: MRK), most recently as a Director of Research Laboratories at Merck & Co.’s Boston, Massachusetts laboratories. He formerly served on the board of Karyopharm Therapeutics, Inc. (Nasdaq: KPTI). Dr. Munoz received his Ph.D. in Organic Chemistry from the University of Toronto and an M.Sc. in Chemistry from Brock University. He also completed postdoctoral training at the Scripps Research Institute.
As the Chief Scientific Officer of Proteostasis Therapeutics Inc, the total compensation of Benito Munoz at Proteostasis Therapeutics Inc is $646,682. There are 2 executives at Proteostasis Therapeutics Inc getting paid more, with Meenu Chhabra having the highest compensation of $1,980,720.
Benito Munoz is 58, he's been the Chief Scientific Officer of Proteostasis Therapeutics Inc since 2017. There are 3 older and 5 younger executives at Proteostasis Therapeutics Inc. The oldest executive at Proteostasis Therapeutics Inc is Franklin Berger, 70, who is the Independent Chairman of the Board.
Benito's mailing address filed with the SEC is C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON, MA, 02135.
Over the last 9 years, insiders at Proteostasis Therapeutics Inc have traded over $9,140,918 worth of Proteostasis Therapeutics Inc stock and bought 12,301,024 units worth $94,383,855 . The most active insiders traders include M James Barrett, Llc Fmr und Bioventures Ltd Novartis Ag.... On average, Proteostasis Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $3,463,082. The most recent stock trade was executed by Enterprise Associates 12, L... on 26 November 2019, trading 1,283,919 units of PTI stock currently worth $3,222,637.
Proteostasis Therapeutics Inc executives and other stock owners filed with the SEC include: